Newborn infant disorders

Our neonatal care specialists are medically equipped and trained to handle virtually any problem that you or your baby may encounter before, during or following birth. From taking care of mothers with high-risk pregnancies to treating at-risk newborns, our medical team is ready to serve your family. Some of the most common newborn conditions we treat include:

  • Birth asphyxia
  • Birth defects
  • Breathing problems
  • Cardiac failure
  • Congenital heart disease
  • Fetal alcohol syndrome
  • Fetal ethanol exposure
  • Gastrointestinal disorders
  • Hematologic conditions
  • Infections
  • Inherited metabolic disorders
  • Low birth weight
  • Malformation syndromes
  • Neonatal lung injury
  • Neurological problems
  • Premature birth
  • Severe respiratory distress
  • Sleep apnea
Health Encyclopedia

Hurler syndrome

Low nasal bridge
Low nasal bridge

Definition

  

Hurler syndrome is a rare, inherited disease of metabolism in which a person cannot break down long chains of sugar molecules called glycosaminoglycans (formerly called mucopolysaccharides).

Hurler syndrome belongs to a group of diseases called mucopolysaccharidoses, or MPS.

See also:


Alternative Names

  

Alpha-L-iduronate deficiency; Mucopolysaccharidosis type I; MPS I H


Causes, incidence, and risk factors

  

Persons with Hurler syndrome do not make a substance called lysosomal alpha-L-iduronidase. This substance, called an enzyme, helps break down long chains of sugar molecules called glycosaminoglycans (formerly called mucopolysaccharides). These molecules are found throughout the body, often in mucus and in fluid around the joints.

Without the enzyme, glycosaminoglycans build up and damage organs, including the heart. Symptoms can range from mild to severe.

Hurler syndrome is inherited, which means that your parents must pass the disease on to you. Both parents need to pass down the faulty gene in order for you to develop Hurler syndrome.

Hurler syndrome is a type of mucopolysaccharidosis called MPS I. Hurler syndrome is the most severe type. It is categorized as MPS I H.

The other subtypes of MPS I are:

  • MPS I H-S (Hurler-Scheie syndrome)
  • MPS I S (Scheie syndrome)

Symptoms

  

Symptoms of Hurler syndrome most often appear between ages 3 and 8. Infants with severe Hurler syndrome appear normal at birth. Facial symptoms may become more noticeable during the first 2 years of life.

Symptoms include:


Signs and tests

  

Urine tests are usually done first. These tests may show extra mucopolysaccharides, but they can't determine the specific form of MPS. More specific tests are done to diagnose the disease, including genetic testing for the alpha-L-iduronidase (IDUA) gene.

Other tests may include a spinal x-ray and EKG.


Treatment

  

Enzyme replacement therapy helps the body make alpha-L-iduronidase.

A bone marrow transplant can improve some of the symptoms of the disease. To prevent mental retardation, a bone marrow transplant probably should be done at a very young age.

Other treatments depend on the organs that are affected.


Support Groups

  

For more information and support, contact one of the following organizations:


Expectations (prognosis)

  

Hurler syndrome is a disease with a poor outlook. Children with this disease develop nervous system problems, and can die young.


Calling your health care provider

  

Call your health care provider if you have a family history of Hurler syndrome and are considering having children, or if your child begins to show symptoms of Hurler syndrome.


Prevention

  

Experts recommend genetic counseling and testing for couples with a family history of Hurler syndrome who are considering having children.


References

  

Staba SL, Escolar ML, Poe M, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004 May 6;350(19):1960-9.

National Institute of Neurological Disorders and Stroke. Mucolipidoses Fact Sheet. Office of Communications and Public Liaison. Bethesda, MD; Publication No. 03-5115. February 13, 2007.


 
Review Date: 5/22/2007
Reviewd By: Brian Kirmse, M.D., Department of Human Genetics, Mount Sinai School of Medicine, New York, NY. Review provided by VeriMed Healthcare Network.
Rate this article:
1 Excellent - 4 Poor
Send a Comment:
Type the characters you see in the picture
CAPTCHA code image
Speak the codeChange the code